Anti-Stargazin Antibody [N245/36 (Formerly sold as S245-36)]

Stargazin Antibody [N245/36 (Formerly sold as S245-36)]

Stargazin Antibody [N245/36 (Formerly sold as S245-36)] is a mouse monoclonal antibody directed against Stargazin, offered by Assay Genie for research applications. Reported applications include WB and ICC/IF. Reported reactivity: Human, Mouse and Rat. Supplied as IgG2A, purified by Protein G.

Stargazin, also known as CACNG2, is a transmembrane protein originally classified as a subunit of voltage-gated calcium channels (VGCCs). While it was first thought to stabilize VGCCs in an inactivated state, Stargazin is now recognized for its pivotal role in regulating AMPA-type glutamate receptors (AMPARs) at excitatory synapses. In the central nervous system, Stargazin anchors AMPARs to the postsynaptic membrane and modulates their trafficking, gating, and synaptic localization. This regulation is essential for synaptic plasticity, learning, and memory—processes that are often disrupted in neurodegenerative diseases. Dysfunction of Stargazin or its interaction with AMPARs has been implicated in several neurological disorders, including epilepsy, intellectual disability, and Alzheimer’s disease. Altered Stargazin expression or phosphorylation can impair synaptic strength and contribute to excitotoxicity, a key driver of neuronal death in neurodegeneration. Moreover, Stargazin’s role in maintaining calcium homeostasis and modulating excitatory neurotransmission positions it as a potential therapeutic target for restoring synaptic balance in neurodegenerative conditions. As a critical link between ion channel regulation and synaptic signaling, Stargazin continues to gain attention in neuroscience for its contributions to both normal brain function and disease pathology. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.